Timothy Hughes, MD, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, discusses two clinical trials investigating treatment approaches in chronic myeloid leukemia (CML). Prof. Hughes first highlights the ASCEMBL trial (NCT03106779) comparing the use of asciminib versus bosutinib and reports on the two-year data from this trial. Prof. Hughes then comments on a Canadian study investigating treatment approaches in patients rwhere disease progression was observed whilst taking imatinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Ad boards and research support from Novartis and Takeda